Editorial
These are exciting times for bladder cancer research. Recently we have seen impressive progress in genomics and molecular biology that heralds the most promising period yet for translational and clinical research in this and related diseases. Such a wealth of valuable research deserves a high quality forum, and as Editors-in-Chief, we are delighted to announce the launch of Bladder Cancer (http://www.iospress.nl/journal/bladder-cancer/), the first journal dedicated to the disease. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the bladder and upper urinary tract. The scope also includes ethics, patient advocacy and survivorship issues.
We would like to thank our stellar international Editorial Board (www.iospress.com/bladder-cancer/?tab=editorial-board) who have given the journal their support. The participation of so many of the world’s top scientists and clinicians in the field bodes extremely well for the success of the journal.
As you might expect, the launch issue features a strong line-up of research articles and reviews. In addition, Bladder Cancer will publish commentaries, short communications, and letters-to-the-editor. All articles accepted this year will be published open access free of charge, with online publication rapidly after acceptance and also in quarterly print issues. After this initial free period the journal will offer an affordable open access option.
Bladder Cancer meets an unmet need and consequently, we are confident that will serve our community well. We fully expect that the journal will become an influential force for good in advancing the frontiers of research in the coming years and decades.
Editors-in-Chief
Seth P. Lerner
Scott Department of Urology
Baylor College of Medicine
Houston, Texas, USA
Dan Theodorescu
University of Colorado Cancer Center
Aurora, Colorado, USA
